TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter of fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31,] [Tianyin Pharmaceutical Inc. Second Quarter Fiscal Year 2014 Financial Results Conference Call February 14, 2014 Operator I will now turn the presentation over to James Tong, CFO of the Company. Dr. Tong: Second Quarter of Fiscal 2014 Ended December 31, 2013 Financial Highlights: ● Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K Current Report February 14, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction Identification No.) (IRS Employer of incorporation) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-19T15:53:50+00:00 February 21st, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports Second Quarter Fiscal Year 2014 Financial

[TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter of fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31,] [Tianyin Pharmaceutical Inc. Second Quarter Fiscal Year 2014 Financial Results Conference Call February 14, 2014 Operator I will now turn the presentation over to James Tong, CFO of the Company. Dr. Tong: Second Quarter of Fiscal 2014 Ended December 31, 2013 Financial Highlights: ● Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K Current Report February 14, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction Identification No.) (IRS Employer of incorporation) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-19T15:55:05+00:00 February 21st, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

OSN [Ossen Innovation] 6-K: (Original Filing)

[Ossen Innovation Awarded Title of ‘Outstanding Foreign-Invested Enterprise’ SHANGHAI, February 21, 2014 -- Ossen Innovation Co., Ltd. ("Ossen" or the "Company") (Nasdaq: OSN), a China-based manufacturer of an array of plain surface, rare earth and zinc coated pre-stressed steel materials, today announced that the Company was recently awarded the national title of ‘outstanding foreign-invested enterprise.’ This prestigious recognition is awarded] [FORM 6-K OSSEN INNOVATION CO., LTD. 518 SHANGCHENG ROAD, FLOOR 17, SHANGHAI, 200120, PEOPLE’S REPUBLIC OF CHINA x ¨ Form 20-F ¨ x Yes OSSEN INNOVATION CO., LTD. Description 99.1 Press Release of Ossen Innovation Co., Ltd., dated February 21, 2014 6-K 1 v369358_6k.htm 6-K]

GAGA [Le Gaga] 6-K: (Original Filing)

[Le Gaga First Half FY 2014 Earnings Release February 20, 2014 1 HONG KONG, February 20, 2014 - Le Gaga Holdings Limited (NASDAQ: GAGA) (“Le Gaga” or “the Company”), a leading greenhouse vegetable producer in China, today announced its financial results for the first fiscal half ended December 31, 2013. Highlights of the Six Months Ended December 31, 2013 •] [Le Gaga Holdings Limited Auke Cnossen Chief financial officer Description 99.1 Press release 6-K 1 d682781d6k.htm FORM 6-K]

By | 2016-03-14T05:15:49+00:00 February 21st, 2014|Categories: Chinese Stocks, GAGA, SEC Original|Tags: , , , , , |0 Comments

OSN [Ossen Innovation] 6-K: Ossen Innovation Awarded Title of ‘Outstanding Foreign-Invested Enterprise’

[Ossen Innovation Awarded Title of ‘Outstanding Foreign-Invested Enterprise’ SHANGHAI, February 21, 2014 -- Ossen Innovation Co., Ltd. ("Ossen" or the "Company") (Nasdaq: OSN), a China-based manufacturer of an array of plain surface, rare earth and zinc coated pre-stressed steel materials, today announced that the Company was recently awarded the national title of ‘outstanding foreign-invested enterprise.’ This prestigious recognition is awarded] [FORM 6-K OSSEN INNOVATION CO., LTD. 518 SHANGCHENG ROAD, FLOOR 17, SHANGHAI, 200120, PEOPLE’S REPUBLIC OF CHINA x ¨ Form 20-F ¨ x Yes OSSEN INNOVATION CO., LTD. Description 99.1 Press Release of Ossen Innovation Co., Ltd., dated February 21, 2014 6-K 1 v369358_6k.htm 6-K]

GAGA [Le Gaga] 6-K: Le Gaga First Half FY 2014 Earnings Release

[Le Gaga First Half FY 2014 Earnings Release February 20, 2014 1 HONG KONG, February 20, 2014 - Le Gaga Holdings Limited (NASDAQ: GAGA) (“Le Gaga” or “the Company”), a leading greenhouse vegetable producer in China, today announced its financial results for the first fiscal half ended December 31, 2013. Highlights of the Six Months Ended December 31, 2013 •] [Le Gaga Holdings Limited Auke Cnossen Chief financial officer Description 99.1 Press release 6-K 1 d682781d6k.htm FORM 6-K]

By | 2016-03-14T05:18:15+00:00 February 21st, 2014|Categories: Chinese Stocks, GAGA, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar